Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Neuroblastoma (NB), the most prevalent extracranial solid tumor among children, is characterized by a high rate of metastasis ...

à  Moving next to the TIGIT landscape. In 2024 ... licensed to Gilead represents a novel way to harness IL-18 pathway ...

Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...

The "Poverty, Prosperity, and Planet. Pathways Out of the Polycrisis" report evaluates progress towards these goals. It offers the first global assessment of poverty and shared prosperity ...

The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT’s diverse function in multiple cell types has made it a ...

Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a ...

A viable strategy could be the use of combination immunotherapies targeting multiple immunosuppressive pathways to fully activate T cells and enhance response rates.

AstraZeneca is operationalizing this study. Domvanalimab (Fc-silent anti-TIGIT antibody) plus Zimberelimab (anti-PD-1 antibody) Overall survival data from the Phase 2 EDGE-Gastric study, evaluating ...

Founded in 2015, the company has expedited the development of multiple investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, HIF-2a ...